newsfilter
← Latest News
GlobeNewswire·

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO)